Australia's most trusted
source of pharma news
Tuesday, 24 June 2025
Posted 23 June 2025 PM
Eli Lilly has unveiled game-changing trial results for its daily oral GLP-1 RA pill, and is already drawing up plans for TGA approval.
Results of the Phase 3 ACHIEVE-1 trial were published in The New England Journal of Medicine, and showed that the small molecule GLP-1 receptor agonist orforglipron showed a significant reduction in AC1 compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.